New Drug Treatment Extends Lives Of Men With Prostate Cancer
New therapy tolerated well by most patients
A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months. The study in the May 26, 2011 issue of the New England Journal of Medicine was co-authored by Thomas W. Flaig, MD, medical oncologist at the University of Colorado Hospital’s Tony Grampsas Urologic Oncology Clinic and assistant professor at the University of Colorado School of Medicine.
“Abiraterone acetate is a new, life-extending pill for the treatment of advanced prostate cancer. Unlike the traditional chemotherapy drugs used in these situations, abiraterone is generally very well tolerated,” said Flaig.
The multi-center Phase III clinical trial of 1195 participants looked at the effectiveness of treating patients who had received prior chemotherapy with a combination of abiraterone acetate (ZytigaTM ) and prednisone. When this trial was initiated, there were no treatments that clearly prolonged survival in this late phase of prostate cancer. The patients were randomized to receive abiraterone acetate plus prednisone or a placebo plus prednisone each day. Treatment continued until the cancer progressed, there were unfavorable reactions, a new treatment was initiated or the patient withdrew from the trial.
The study shows participants taking abiraterone acetate lived about four months longer than participants taking the placebo. In addition, more patients receiving abiraterone acetate experienced a significant drop in the PSA blood level than those on the placebo.
“The survival benefit observed in this study is especially notable, since this was seen in the most advanced cases of prostate cancer,” said Flaig. “Other studies are being done to examine the benefit of using abiraterone acetate earlier in the disease process, where it may be even more effective.”
The FDA approved abiraterone acetate at the end of April. The tablet has few side effects but careful medical attention is required to monitor for specific potential side effects including liver blood test changes, low potassium levels, leg swelling and high blood pressure.
University of Colorado Hospital (UCH) is the Rocky Mountain region’s leading academic medical center. It is ranked among the top 10 academic medical centers in the United States by the University HealthSystem Consortium and is ranked as the best hospital in the Denver metro area and one of the best in the country by U.S.News & World Report. UCH is best known as an innovator in patient care and often as one of the first hospitals to bring new medicine to patients’ bedsides. The hospital’s physicians are affiliated with the University of Colorado School of Medicine, part of the University of Colorado system. Based on the expansive Anschutz Medical Campus in Aurora, Colo., the hospital is a central part of one of the country’s only true “Health Care Cities” where patient care, research and education converge to establish the future of health care delivery. For additional news and information, please visit the University of Colorado Denver newsroom.
On the Net: